PRN1008

Unassigned

New Medicines

Pemphigus vulgaris (PV) and pemphigus foliaceus (PF)

Information

New molecular entity
Principia
Principia

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

Brutons tyrosine kinase (BTK) inhibitor (BTK is involved in signalling pathways for most white cells)
Pemphigus vulgaris (PV) is by far the most common variant of pemphigus though this variant is rare. UK incidence is estimated to be 0.68 per 100,000 person years [2].
Pemphigus vulgaris (PV) and pemphigus foliaceus (PF)
Oral